

2018-05-21

Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their capacity to recognize infected macrophages

Jason D. Yang
University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>



Part of the Amino Acids, Peptides, and Proteins Commons, Bacteria Commons, Bacterial Infections and Mycoses Commons, Immunology and Infectious Disease Commons, and the Microbiology Commons

Repository Citation

Yang JD, Mott D, Sutiwisesak R, Lu Y, Raso F, Stowell B, Babunovic GH, Lee J, Carpenter SM, Way SS, Fortune SM, Behar SM. (2018). Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their capacity to recognize infected macrophages. Open Access Articles. <https://doi.org/10.1371/journal.ppat.1007060>. Retrieved from <https://escholarship.umassmed.edu/oapubs/3472>

Creative Commons License



This work is licensed under a [Creative Commons Attribution 4.0 License](https://creativecommons.org/licenses/by/4.0/).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

RESEARCH ARTICLE

Mycobacterium tuberculosis-specific CD4⁺ and CD8⁺ T cells differ in their capacity to recognize infected macrophages

Jason D. Yang¹, Daniel Mott¹, Rujapak Sutiwisesak¹, Yu-Jung Lu¹, Fiona Raso¹, Britni Stowell¹, Greg Hunter Babunovic², Jinhee Lee¹, Steve M. Carpenter¹, Sing Sing Way³, Sarah M. Fortune², Samuel M. Behar^{1*}

1 Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, **2** Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, **3** Division of Infectious Disease, Cincinnati Children's Hospital, Cincinnati, Ohio, United States of America

* samuel.behar@umassmed.edu



OPEN ACCESS

Citation: Yang JD, Mott D, Sutiwisesak R, Lu Y-J, Raso F, Stowell B, et al. (2018) *Mycobacterium tuberculosis*-specific CD4⁺ and CD8⁺ T cells differ in their capacity to recognize infected macrophages. PLoS Pathog 14(5): e1007060. <https://doi.org/10.1371/journal.ppat.1007060>

Editor: David M. Lewinsohn, Portland VA Medical Center, Oregon Health and Science University, UNITED STATES

Received: February 22, 2018

Accepted: April 27, 2018

Published: May 21, 2018

Copyright: © 2018 Yang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was funded by grants from the National Institutes of Health (R01 AI106725, R01 AI123286). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Containment of *Mycobacterium tuberculosis* (Mtb) infection requires T cell recognition of infected macrophages. Mtb has evolved to tolerate, evade, and subvert host immunity. Despite a vigorous and sustained CD8⁺ T cell response during Mtb infection, CD8⁺ T cells make limited contribution to protection. Here, we ask whether the ability of Mtb-specific T cells to restrict Mtb growth is related to their capacity to recognize Mtb-infected macrophages. We derived CD8⁺ T cell lines that recognized the Mtb immunodominant epitope TB10.4_{4–11} and compared them to CD4⁺ T cell lines that recognized Ag85b_{240–254} or ESAT6_{3–17}. While the CD4⁺ T cells recognized Mtb-infected macrophages and inhibited Mtb growth in vitro, the TB10.4-specific CD8⁺ T cells neither recognized Mtb-infected macrophages nor restricted Mtb growth. TB10.4-specific CD8⁺ T cells recognized macrophages infected with *Listeria monocytogenes* expressing TB10.4. However, over-expression of TB10.4 in Mtb did not confer recognition by TB10.4-specific CD8⁺ T cells. CD8⁺ T cells recognized macrophages pulsed with irradiated Mtb, indicating that macrophages can efficiently cross-present the TB10.4 protein and raising the possibility that viable bacilli might suppress cross-presentation. Importantly, polyclonal CD8⁺ T cells specific for Mtb antigens other than TB10.4 recognized Mtb-infected macrophages in a MHC-restricted manner. As TB10.4 elicits a dominant CD8⁺ T cell response that poorly recognizes Mtb-infected macrophages, we propose that TB10.4 acts as a decoy antigen. Moreover, it appears that this response overshadows subdominant CD8⁺ T cell response that can recognize Mtb-infected macrophages. The ability of Mtb to subvert the CD8⁺ T cell response may explain why CD8⁺ T cells make a disproportionately small contribution to host defense compared to CD4⁺ T cells. The selection of Mtb antigens for vaccines has focused on antigens that generate immunodominant responses. We propose that establishing whether vaccine-elicited, Mtb-specific T cells recognize Mtb-infected macrophages could be a useful criterion for preclinical vaccine development.

Author summary

Immunodominant antigens elicit a large majority of T cells during an infection, and it is presumed that these T cells go on to recognize infected cells. Immunodominant antigens produced by *Mycobacterium tuberculosis* (Mtb) have been incorporated into vaccines, but whether T cells specific for these antigens recognize Mtb-infected cells is inconsistent. One of these is TB10.4 (EsxH), and after aerosol infection in mice, up to 40% of lung CD8 T cells recognize TB10.4. Vaccination with TB10.4_{4–11} peptide elicits a robust response and TB10.4-specific memory CD8 T cells develop. However, these mice are not protected against Mtb challenge. In trying to understand why this vaccine fails, we discovered that TB10.4-specific CD8 T cells do not recognize Mtb-infected macrophages *in vitro*. In contrast, under identical conditions, Ag85b-specific CD4 T cells recognize Mtb-infected macrophages and inhibit Mtb growth. In contrast, polyclonal CD4 and CD8 T cells from the lungs of infected mice recognize Mtb-infected macrophages, suggesting macrophages present antigens other than the immunodominant TB10.4 antigen. Thus, we conclude that TB10.4 is a decoy antigen that elicits a dominant CD8 T cell response that poorly recognizes Mtb-infected macrophages, and allows Mtb to evade CD8 immunity. Instead, this response may benefit Mtb by promoting inflammation. We propose that the poor ability of CD8 T cells to mediate protection might arise because the dominant T cells are unable to recognize infected macrophages. Identifying antigens that are presented by infected cells should be prioritized, as their inclusion in vaccines may enhance the expansion of T cells that mediate protection.

Introduction

Unlike most disease-causing pathogens, *Mycobacterium tuberculosis* (Mtb), the cause of tuberculosis (TB), persists in humans because of its highly evolved ability to evade and subvert the host immunity [1]. Mtb subverts vesicular trafficking, prevents phagolysosome fusion, and replicates in an intracellular niche within macrophages, allowing it to evade detection by humoral immunity [2]. Mtb also delays the initiation and recruitment of T cell immunity to the lung, promoting the establishment of a persistent infection [3]. Despite these challenges, T cell immunity does occur and plays an essential role in controlling the infection in both mice and humans [3–5]. With 10 million new TB cases annually, an effective vaccine would offer a cost-effective way to prevent TB and attenuate this persistent global pandemic. Given the importance of T cells during host defense, strategies for TB vaccines largely aim at generating memory T cells rather than neutralizing antibodies. Most subunit vaccines incorporate immunodominant Mtb antigens, which elicit large T cell responses [6]. Several immunodominant antigens have been identified in the murine TB model, including Ag85a, Ag85b, CFP-10, ESAT-6 and TB10.4 [7]. T cell responses to these antigens are also frequently detectable in Mtb-infected people, and these highly prevalent responses represent the basis for TB immunodiagnostic tests [8]. By incorporating these immunodominant antigens into vaccines, the expectation is that antigen-specific T cells will contain the infection before Mtb can establish a niche and evade host immunity [6].

T cell recognition of Mtb-infected macrophages is fundamental to containment of TB infection. Srivastava et al elegantly showed this by using mixed bone marrow (BM) chimeric mice made from wild type (WT) and major histocompatibility complex class II (MHC class II) deficient BM [9]. Following infection, polyclonal CD4⁺ T cells suppressed Mtb growth more efficiently in MHC class II-expressing cells than in MHC class II-deficient cells. This data convincingly argues

that cognate recognition (i.e., T cell receptor (TCR) mediated recognition) of infected cells by polyclonal CD4⁺ T cells limits bacterial growth. However, whether this protection comes from T cells recognizing immunodominant or subdominant antigens remains unknown. In fact, even though many presume that Mtb-infected cells present immunodominant antigens, the data validating this assumption is surprisingly inconsistent. While there is consensus that Mtb-infected cells present ESAT-6, the data concerning Ag85b presentation is more complicated [10–13]. Ag85b₂₄₀₋₂₅₄ elicits a CD4⁺ T cell response early after infection, but Mtb reduces Ag85b production within three weeks after in vivo infection [12]. Thus, while Ag85b₂₄₀₋₂₅₄-specific CD4⁺ T cells can recognize dendritic cells (DC) from infected mice 14 days post infection [14], there is little recognition of Mtb-infected cells by Ag85b₂₄₀₋₂₅₄-specific CD4⁺ T cells in vivo by day 21 [12]. Furthermore, Mtb has other mechanisms to evade T cell recognition, including dysregulating MHC class II expression and inhibiting antigen presentation by stimulating antigen export by the infected antigen presenting cells (APCs) [1, 12, 13, 15]. Whether the immunodominant antigens recognized by CD8⁺ T cells are presented by Mtb-infected macrophages remains unknown. Here, we investigated cognate T cell recognition of Mtb-infected macrophages by CD8⁺ T cells specific to the immunodominant antigen TB10.4.

TB10.4 (EsxH) is an ESAT-6-like protein secreted by the ESX-3 type VII secretion system, important in iron and zinc acquisition, and although its requirement for bacterial growth depends on the culture conditions, it is essential for Mtb growth in macrophages and virulence in vivo [16–18]. Following Mtb infection, TB10.4 is a target of CD4⁺ and CD8⁺ T cell responses in humans and mice [19–23]. In Mtb-infected mice, TB10.4 elicits immunodominant responses in both BALB/c and C57BL/6 mice, and 30–50% of lung CD8⁺ T cells are specific to single epitopes [19, 20]. We previously isolated TB10.4-specific CD8 T cells using K^b/TB10.4_{4–11} tetramers, followed by single cell sorting and PCR to identify the TB10.4_{4–11}-specific TCRs. These TCRs were cloned in retroviral vectors to produce retrogenic (Rg) mice [20]. Following transfer to Mtb-infected mice, naïve (CD44^{lo}CD62L^{hi}) TB10.4_{4–11}-specific Rg CD8 T cells became activated first in the LN and then trafficked to the lung, where they matured into effector CD8 T cells [20, 24]. Whether these TB10.4-specific CD8⁺ T cells can mediate protection is unclear. Adoptive transfer of TB10.4-specific CD8⁺ T cells into Mtb-infected, immunocompromised mice reduces the bacterial burden and promotes host survival [20]. However, despite eliciting large numbers of TB10.4-specific CD8⁺ T cells, a vaccine incorporating the H-2 K^b-restricted epitope, TB10.4_{4–11}, fails to protect mice from Mtb infection [24]. We hypothesize that the inability of TB10.4-specific CD8⁺ T cells to mediate protection is due to inefficient recognition of Mtb-infected macrophages.

We used primary CD4⁺ and CD8⁺ T cell lines to investigate the recognition of Mtb-infected macrophages by T cells specific to Ag85b, ESAT-6, or TB10.4. Ag85b- and ESAT-6-specific CD4⁺ T cells recognized Mtb-infected macrophages, but under the same conditions, TB10-specific CD8⁺ T cells did not recognize infected macrophages or inhibit bacterial growth. This was true even upon examination of numerous conditions and permutations including length of infection, duration of T cell and macrophage co-culture, and multiplicity of infection. TB10.4-specific CD8⁺ T cells did recognize macrophages infected with recombinant *Listeria monocytogenes* expressing TB10.4, but only if the bacilli could escape into the cytosol. However, overexpressing TB10.4 in Mtb did not confer recognition. Importantly, macrophages pulsed with irradiated bacteria efficiently cross-presented TB10.4 to CD8⁺ T cells, suggesting that live Mtb actively inhibited presentation. Interestingly, polyclonal CD8⁺ T cells specific for Mtb antigens other than TB10.4 recognized Mtb-infected macrophages in a MHC class I-restricted manner. Thus, while TB10.4-specific CD8⁺ T cells do not recognize Mtb-infected macrophages, there exist other CD8⁺ T cells that recognize subdominant antigens presented by Mtb-infected cells. Based on these data, we propose that TB10.4 is a decoy antigen: it elicits a massive and persistent CD8⁺ T

cell response, which cannot recognize Mtb-infected macrophages. Such a decoy antigen may distract the CD8⁺ response from focusing on subdominant antigens presented by infected cells, leading to evasion from host immunity.

Results

TB10.4-specific CD8⁺ and Ag85b-specific CD4⁺ T cell lines sensitively recognize their cognate antigens

To study T cell recognition of Mtb-infected macrophages, we established antigen-specific T cell lines, which unlike T cell hybridomas, facilitate the study of T cell function as well as recognition. The TB10.4_{4–11}-specific CD8⁺ T cell line, referred to hereafter as TB10Rg3, has a distinct TCR cloned originally from TB10.4_{4–11}-tetramer⁺ CD8⁺ T cells isolated from infected mice and expressed in retrogenic mice [20]. The Ag85b_{240–254}-specific CD4⁺ T cell line, referred to hereafter as P25 cells, was derived from P25 TCR transgenic mice [25]. To confirm their antigen-specificity, we co-cultured the P25 or TB10Rg3 T cells with thioglycolate-elicited peritoneal macrophages (TGPMs) pulsed with or without their cognate peptides and then measured their expression of CD69 and Nur77. While both CD69 and Nur77 are T cell activation markers, increases in Nur77 expression indicate TCR-mediated activation more specifically [26, 27]. After co-culture with TGPMs pulsed with Ag85b_{240–254} peptide, Nur77 expression by P25 cells peaked after 2 hours (Fig 1A and 1B), while CD69 expression continued to increase (Fig 1C and 1D). TB10Rg3 T cells exhibited similar Nur77 and CD69 expression patterns after their co-culture with TGPMs pulsed with the TB10.4_{4–11} peptide (IMYNYPAM) but not with a control peptide (IMANAPAM) (Fig 1E–1H). Since the increase in Nur77 expression was transient, we next tested whether CD69 and IFN γ could be useful markers of antigen recognition for longer experiments. During 72 hours of co-culture with peptide-pulsed TGPMs, P25 and TB10Rg3 T cells continued to express CD69 and secreted IFN γ in a peptide dose-dependent manner (Fig 1I–1L). P25 T cells also responded specifically to macrophages pulsed with Ag85b peptides and not TB10.4 peptides (S1 Fig). These experiments show that P25 and TB10Rg3 T cells can recognize their cognate antigens presented by TGPMs, both in short-term and long-term co-culture assays.

Ag85b-specific CD4⁺ T cells, but not TB10.4-specific CD8⁺ T cells, restrict intracellular bacterial replication

Given that a primary function of T cells during Mtb infection is to restrict bacterial growth, we determined whether these T cell lines could limit intracellular mycobacterial growth *in vitro*. We infected TGPMs with H37Rv, a virulent Mtb strain that expresses both TB10.4 and Ag85b *in vitro* [22, 28]. To assess whether any bacterial growth inhibition observed was dependent on cognate recognition, we infected both MHC-matched (i.e., H-2^b) and mismatched (i.e., H-2^k) macrophages. T cells were added on day 1 post-infection, and the number of colony forming units (CFU) was assayed 96 hours later. In the absence of T cells, Mtb grew significantly ($p < 0.01$) (Fig 2). P25 T cells significantly inhibited intracellular bacterial growth in H37Rv-infected TGPMs ($p < 0.0001$). Addition of Ag85b peptide to the infected macrophages did not further enhance the ability of P25 T cells to inhibit bacterial growth, suggesting that their activation was maximal. As expected, P25 T cells only inhibited bacterial growth in MHC-matched macrophages, indicating that growth inhibition mediated by T cells required cognate recognition under these conditions.




Fig 1. TB10.4-specific CD8⁺ (TB10Rg3) and Ag85b-specific CD4⁺ (P25) T cells both recognize their cognate peptides. (a) Representative histogram of Nur77 expression in P25 T cells after 2 hours of co-culture with macrophages and (b) time course of Nur77 MFI in P25 T cells. (c) Representative histogram of CD69 in P25 T cells after 2 hours of co-culture with macrophages and (d) time course of CD69 MFI in P25 T cells. (e) Representative histogram of Nur77 in TB10Rg3 T cells after 2 hours of co-culture and (f) time course of Nur77 MFI in TB10Rg3 T cells. (g) Representative histogram of CD69 in TB10Rg3 T cells at 2 hours of co-culture with macrophages and (h) time course of CD69 MFI in TB10Rg3 T cells. (i) CD69 MFI and (j) IFN γ production by P25 T cells after 72 hours of co-culture. (k) CD69 MFI and (l) IFN γ production by TB10Rg3 cells after 72 hours of co-culture. MFI, mean fluorescence intensity; mp, macrophage.

<https://doi.org/10.1371/journal.ppat.1007060.g001>

In contrast, TB10Rg3 T cells did not inhibit bacterial growth (Fig 2). We considered whether the inability of TB10Rg3 to inhibit bacterial growth was due to a lack of recognition of the infected macrophages or a defect in the T cells' effector functions. When Mtb-infected TGPMs were pulsed with the TB10.4₄₋₁₁ peptide for one hour prior to adding the T cells, TB10Rg3 T cells significantly reduced bacterial growth ($p < 0.0001$) (Fig 2A). Thus, under the same conditions where P25 T cells significantly suppressed intracellular Mtb growth in a MHC-restricted manner, TB10Rg3 T cells failed to inhibit bacterial growth.

We next considered whether the inability of TB10Rg3 to restrict intracellular bacterial growth was true for other TB10.4₄₋₁₁-specific CD8⁺ T cells. To obtain TCRs representative of




Fig 2. Ag85b-specific CD4⁺ T cells, but not TB10.4-specific CD8⁺ T cells, inhibit bacterial growth *in vitro*. (a) Matched (H-2^b) or mismatched (H-2^k) macrophages were infected with H37Rv for 2 hours, and then, one day post-infection, T cells were added. Separately, TB10.4 or Ag85b peptide was added to Mtb-infected (H-2^b) macrophages, and then T cells were added. CFU were determined 4 days later. (b) C57BL/6 macrophages were infected with H37Rv as described above. The next day, TB10.4₄₋₁₁ peptide and Ag85b₂₄₀₋₂₅₄ peptide was added for 1 hour, indicated as “+,” to wells that would later receive TB10.4₄₋₁₁-specific CD8⁺ and P25 CD4⁺ T cells, respectively. Subsequently, unbound peptides were washed away and TB10Rg3, TB10RgP, TB10RgL, TB10RgR, or P25 T cells were added. CFUs were determined 4 days later. Results are representative of at least three experiments. Statistical testing was by one-way ANOVA, using the Dunnett posttest compared to d5. *, #, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.0001.

<https://doi.org/10.1371/journal.ppat.1007060.g002>

other clonally expanded TB10.4₄₋₁₁-specific CD8⁺ T cells, TB10.4₄₋₁₁-tetramer⁺ CD8⁺ T cells from Mtb-infected C57BL/6 mice were single cell sorted, and both the TCR CDR3α and CDR3β regions were sequenced (S2 Fig). Three TCRs representative of clonally expanded T

cells (TB10RgL, TB10RgR, and TB10RgQ) were cloned (S2 Fig). In addition, a fourth TCR (TB10RgP), not previously identified by NexGen sequencing, was also cloned. All these TCRs responded specifically to the TB10.4_{4–11} epitope and expressed TCRs distinct from TB10Rg3 (S3 Fig). We generated T cell lines from these retrogenic mice, as described for TB10Rg3. TB10RgP, TB10RgL, and TB10RgR did not inhibit bacterial growth (Fig 2B). However, if the Mtb-infected macrophages were pulsed with the TB10.4_{4–11} peptide before T cell addition, then TB10RgP, TB10RgL, and TB10RgR T cells all inhibited bacterial growth significantly (Fig 2B). Since TB10.4_{4–11}-specific CD8⁺ T cells only inhibited bacterial growth when their cognate peptide was added to Mtb-infected macrophages, we conclude that, although they express the effector function required to restrict intracellular bacterial growth, these TB10.4_{4–11}-specific CD8⁺ T cells do not recognize Mtb-infected macrophages.

Ag85b-specific CD4⁺ T cells, but not TB10.4-specific CD8⁺ T cells, recognize Mtb-infected macrophages

To further investigate TB10Rg3 and P25 T cells recognition of Mtb-infected cells, we next investigated the kinetics of Mtb antigen presentation. After Mtb infection, TGPMs were cultured for various lengths of time before adding the T cells. To assay antigen presentation, we added the T cells for two hours and then measured Nur77 and CD69 (see Fig 1 for kinetics). We first examined recognition on day 0 by adding T cells immediately after infection, and we infected macrophages at a high MOI (average effective MOI of 1.57 to 1.62) to ensure that a large amount of bacterial and antigens may be present. P25 T cells recognized Mtb-infected macrophages based on the induction of Nur77 and CD69 (Fig 3A and 3B). Under these conditions, there was no increase in Nur77 or CD69 expression by TB10Rg3 T cells (Fig 3C and 3D). We next chose later time points, which might allow Mtb to adapt to the intracellular environment and potentially let the TB10.4 antigen accumulate. We first infected cells at a lower MOI (average effective MOI of 0.2 to 0.8). TB10Rg3 T cells were added to infected macrophages on days 1, 3, or 5 post-infection. Again, we did not observe any increase in Nur77 or CD69 expression (Fig 3E and 3F). As a control for T cell health and function, we co-cultured TB10.4_{4–11}-peptide-pulsed-, uninfected-macrophages with the TB10Rg3 T cells and observed significant increases in their Nur77 and CD69 expression (Fig 3). We also considered whether a higher MOI may lead to more presentation. We infected macrophages at an average effective MOI of 1.65 to 5.98 and added TB10Rg3 T cells 1 or 2 days post infection. Again, we did not detect induction of Nur77 or CD69 expression when TB10Rg3 T cells were co-cultured with the highly infected macrophages (S4 Fig). We did not examine recognition at high MOI on days later than day 2 because of excessive death of the macrophages. Instead, we explored an alternative approach to increasing antigen abundance, as described below.

Despite assessing recognition on multiple days, we considered whether the short assay period (i.e. 2 hours) might not detect recognition of Mtb-infected macrophages by TB10Rg3 T cells, especially if presentation of TB10.4 is inefficient or asynchronous. Therefore, we used IFN γ production as a cumulative indicator of T cell activation during a 72-hour co-culture experiment. Since cytokine-driven activation (e.g., IL-12, IL-18) can stimulate IFN γ production by T cells independently of TCR signaling, we used MHC-matched (H-2^b) or mismatched (H-2^k) TGPM to assess cognate recognition [27, 29–31]. As the infectious dose (MOI, multiplicity of infection) increased, P25 T cells produced more IFN γ when co-cultured with MHC-matched, but not MHC-mismatched, Mtb-infected TGPMs (Fig 3G). In contrast, TB10Rg3 T cells did not produce IFN γ when co-cultured with Mtb-infected TGPMs (Fig 3H). As before, TB10Rg3 T cells produced IFN γ when co-cultured with uninfected macrophages pulsed with the TB10.4_{4–11} peptide (Fig 3H).




Fig 3. Ag85b-specific CD4⁺ T cells, but not TB10.4-specific CD8⁺ T cells, recognize Mtb-infected macrophages. (a-d) T cells were co-cultured with peptide-pulsed, Mtb-infected (at MOI 1, 5, or 10), or uninfected macrophages for 2 hours. (a) Representative histogram of Nur77 expression in P25 T cells and the normalized Nur77 MFI. (b) Representative histogram of CD69 expression in P25 T cells and the normalized CD69 MFI. (c) Representative histogram of Nur77 in TB10Rg3 T cells and the normalized Nur77 MFI. (d) Representative histogram of CD69 expression in TB10Rg3 T cells and the normalized CD69 MFI. (e-f) TB10Rg3 T cells were co-cultured with uninfected, peptide-pulsed, or Mtb-infected macrophages for 2 hours on d1, d3, and d5 post infection. Normalized expression of (e) Nur77 or (f) CD69 by TB10Rg3 T cells. P25 (g) or TB10Rg3 (h) T cells were co-cultured with uninfected, peptide-pulsed, or Mtb-infected macrophages, and IFN γ production was measured after 72 hours. (i) TB10Rg3, TB10RgP, TB10RgL, TB10RgR, or P25 T cells were cultured with uninfected, Mtb-infected, or peptide-pulsed macrophages. After 3 days, IFN γ in the supernatants was measured. Figures are representative of at least 5 (a-d, TB10Rg3), 2 (a-d, P25), 3 (e-h), or 2 (i) experiments. Statistical analysis was done by one-way ANOVA with Dunnett posttest (a-d) or two-way ANOVA with Sidak posttest (g-h). *, p<0.05; **, p<0.01; and ***, p<0.005.

<https://doi.org/10.1371/journal.ppat.1007060.g003>

We next used the TB10.4₄₋₁₁-specific CD8⁺ T cell lines TB10RgP, TB10RgL and TB10RgR to address whether TB10.4₄₋₁₁-specific CD8⁺ T cells other than TB10Rg3 can recognize Mtb-infected macrophages. While the TB10RgP, TB10RgL, and TB10RgR CD8⁺ T cell lines produced IFN γ when cultured with uninfected macrophages pulsed with the TB10.4₄₋₁₁ peptide, none produced IFN γ following a 72-hour co-culture with Mtb-infected macrophages (Fig 3I). These data show that, regardless of the time point of T cell addition or the length of co-culture, P25 T cells, but not TB10.4₄₋₁₁-specific CD8⁺ T cells, recognized Mtb-infected macrophages, based on their increased Nur77 and CD69 expression as well as their IFN γ production.

TB10.4-specific CD8⁺ T cells do not recognize lung cells from Mtb-infected mice

During *in vivo* infection, Mtb infects a variety of myeloid cells, and this diversity changes over the course of the infection [32–34]. We considered that lung myeloid cells from Mtb-infected mice are more physiologically relevant than TGPMs. Thus, we isolated MHC class II⁺ lung cells from Erdman-infected, RAG-1-deficient mice 4 weeks post-infection and tested their ability to present Mtb antigens to TB10Rg3 T cells. We used RAG-1-deficient mice because of the possibility that CD8⁺ T cells in the lungs of Mtb-infected, wild type mice may recognize and eliminate any lung cells presenting the TB10.4 antigen. Since Mtb downregulates Ag85b expression by 3 weeks post infection [11, 12], we used an ESAT-6-specific CD4⁺ T cell line derived from C7 transgenic mice, which we refer to as C7 T cells [10, 35]. The immunodominant antigen ESAT-6 retains high levels of expression throughout infection and elicits a dominant CD4⁺ T cell response in C57BL/6 mice [11]. Due to the difficulty in obtaining large numbers of MHC class II⁺ cells from uninfected, RAG-1-deficient mice, we used TGPMs from age-matched, RAG-1-deficient mice as a source of uninfected, inflammatory macrophages. We stained C7 or TB10Rg3 T cells with 5 μ M of the proliferation dye eFluor450 (eBioscience) before co-culturing them with the lung myeloid cells. After 72 hours, we measured the T cell proliferation as a marker of T cell recognition. C7 T cells proliferated extensively when co-cultured with the infected lung myeloid cells but not when co-cultured with uninfected TGPMs (Fig 4A and 4B). In contrast, TB10Rg3 T cells did not proliferate when co-cultured with the lung myeloid cells (Fig 4C and 4D). To assess whether TB10Rg3 T cells could proliferate if TB10.4 was present, we pulsed the lung APCs with the TB10.4₄₋₁₁ peptide for 1 hour before adding the TB10Rg3 T cells. As predicted, TB10Rg3 T cells proliferated after 72 hours of co-culture with peptide-pulsed, lung myeloid cells (Fig 4C and 4D).

We considered the possibility that Mtb in lung myeloid cells may not grow well *in vitro*, leading to altered antigen abundance that could affect T cell recognition. To address this possibility, we measured the bacterial burden in the lung myeloid cells. There was a 3-fold increase in the bacterial numbers between the beginning (d1) and the end (d4) of the experiment, indicating that the bacteria remained viable (Fig 4E). Together, these data indicate that, under the




Fig 4. TB10Rg3 CD8⁺ T cells do not recognize lung APCs from infected mice. (a-d) T cell proliferation after coculture with lung APC from infected mice, with or without cognate peptide, or uninfected TGPM, based on eFluor450 fluorescence dilution after 72 hours. Representative flow plot (a) and quantification (b) of C7 T cell proliferation. Representative flow plot (c) and quantification (d) of TB10Rg3 T cell proliferation. (e) Bacterial burden in the lung APCs during *in vitro* culture over the course of the experiment in the absence of T cells. Representative of 4 (TB10Rg3) or 2 (C7) experiments.

<https://doi.org/10.1371/journal.ppat.1007060.g004>

conditions in which C7 T cells recognized lung myeloid cells from Mtb-infected mice, TB10Rg3 T cells did not recognize these lung myeloid cells.

TB10Rg3 CD8⁺ and P25 CD4⁺ T cells recognize macrophages infected with TB10.4-or Ag85b-expressing *Listeria*


We next investigated whether the location of the antigen might affect the presentation of TB10.4 since the MHC class I antigen presentation pathway primarily samples the cytosol, whereas Mtb is a classic phagosomal pathogen. TB10.4-specific CD8⁺ T cells are primed and expanded during Mtb infection, so the TB10.4 antigens must be cross-presented; however, whether Mtb-infected macrophages can competently cross-present mycobacterial antigens is unknown. We investigated these possibilities using Δ LLO or Δ ActA mutant strains of *Listeria monocytogenes* engineered to express the full length TB10.4 protein, hereafter referred to as

Δ LLO.TB10.4 or Δ ActA.TB10.4, respectively. Both are attenuated strains: the Δ LLO.TB10.4 mutant cannot escape from the vacuole, while the Δ ActA.TB10.4 mutant can escape from the vacuole but not from the cell. Hence, the TB10.4 protein made by the Δ LLO.TB10.4 strain will remain trapped in the phagosome, but the TB10.4 protein made by the Δ ActA.TB10.4 strain will gain access to the cytosol.


TB10Rg3 T cells recognized Δ ActA.TB10.4-infected TGPMs based on an increased frequency of Nur77-expressing cells ($p < 0.005$) and the Nur77 MFI of all TB10Rg3 T cells ($p < 0.005$) (Fig 5A–5C). Bafilomycin, which inhibits vacuolar acidification and impairs the entry of the Δ ActA.TB10.4 strain into the cytosol, diminished the frequency of Nur77-expressing cells ($p < 0.005$) and Nur77 MFI ($p < 0.01$) (Fig 5A, top, Fig 5B and 5C). In contrast, TB10Rg3 T cells co-cultured with Δ LLO.TB10.4-infected TGPMs showed no increase in the frequency of Nur77-expressing cells or the Nur77 MFI (Fig 5A bottom, Fig 5D and 5E). If recombinant listeriolysin (rLLO), the protein missing from the Δ LLO.TB10.4 strain, was added to the infected macrophages, an increase in the frequency of Nur77-expressing TB10Rg3 T cells ($p < 0.01$) and the Nur77 MFI ($p < 0.01$) became apparent. We also determined whether P25 T cells recognized Ag85b-expressing *Listeria monocytogenes* using the recombinant *Listeria* strains Δ ActA.Ag85b and Δ LLO.Ag85b. Based on the propensity of MHC class II to present extracellular and vacuolar antigens, P25 cells recognized TGPMs infected with either Δ ActA.Ag85b or Δ LLO.Ag85b, based on an increase in the frequency of Nur77-expressing T cells and Nur77 MFI ($p < 0.005$) (Fig 5G and 5H). These results show that 1) TGPMs can efficiently process the full length TB10.4 protein and present the TB10.4_{4–11} epitope via MHC class I; 2) this process is more efficient when the bacteria are in the cytosol; and 3) TB10Rg3 T cells can efficiently recognize TB10.4_{4–11} presented during a live infection.

TB10.4-specific CD8⁺ T cells do not recognize Mtb overexpressing TB10.4


We considered several additional possibilities as to why the TB10Rg3 T cells did not recognize Mtb-infected macrophages. Antigen abundance can affect T cell recognition, so we next tested whether increasing the level of TB10.4 protein expression might enhance TB10Rg3 T cell recognition of Mtb-infected macrophages. Since Mtb secretes esxH (TB10.4) together with esxG as a heterodimer [36], we developed a recombinant strain of H37Rv (esxGH-OE.Mtb), which overexpresses both esxG and esxH under the control of a tet^{ON} promoter. After tetracycline induction for 24 hours, we detected increased protein expression of TB10.4 (esxH) as well as increased mRNA expression of esxG and esxH (Fig 6A and 6B). A second strain, Ag85b-OE.Mtb, was used to show the specificity of the anti-TB10.4 antibody. When Ag85b was induced, TB10.4 expression was unaltered (Fig 6A). The expression of GroEL2, a chaperonin protein, was used as loading control and for normalization of protein signal (Fig 6A). When detecting the mRNA expression, we probed for sigA, which encodes for a Mtb RNA polymerase factor, and fbpB, which encodes for Ag85b, as well to verify that the esxGH-OE.Mtb strain specifically overexpressed esxGH and not other proteins (Fig 6B). Prior to in vitro infection, we treated esxGH-OE.Mtb with or without tetracycline. The next day, TGPMs were infected with induced or uninduced esxGH-OE.Mtb. P25 T cells produced similar amounts of IFN γ when co-cultured with macrophages infected with either uninduced or induced esxGH-OE.Mtb, which was expected since Ag85b expression should not be altered (Fig 6C). Despite increasing the production of TB10.4 by Mtb, TB10Rg3 T cells still did not recognize Mtb-infected macrophages (Fig 6D). Although we cannot be certain that the induction of EsxGH leads to an increased amount of antigen delivered to the antigen processing pathway, this result suggests that antigen abundance is not limiting TB10.4-specific CD8⁺ T cell recognition of Mtb-infected macrophages.




B. TB10Rg3




D. TB10Rg3




G. P25



C.



E.



H.




Fig 5. TB10Rg3 and P25 T cells can recognize macrophages infected with *Listeria monocytogenes* expressing TB10.4 and Ag85b proteins, respectively. (a) Representative flow plots showing Nur77 induction by TB10Rg3 T cells after co-culture with macrophages infected with Δ ActA.TB10 (top row) or Δ LLO.TB10 (bottom row) *Listeria*. (b) Analysis of the frequency of Nur77-expressing TB10Rg3 T cells (b, d), or normalized MFI (c, e), after co-culture with Δ ActA.TB10 (b, c) or Δ LLO.TB10 (d, e) infected macrophages. (f) Representative flow plots showing Nur77 induction by P25 population after co-culture with macrophages infected with Δ ActA.TB10 (top row) or Δ LLO.TB10 (bottom row) *Listeria*. (g) Analysis of the frequency of Nur77-expressing P25 T cells and (h) normalized MFI of P25 T cells. Representative of at least two experiments. Statistical testing by one-way ANOVA with Dunnett posttest. *, $p < 0.05$; **, $p < 0.01$; and ***, $p < 0.005$.

<https://doi.org/10.1371/journal.ppat.1007060.g005>

Mtb infection does not significantly impair MHC class I and II expression by macrophages

We also investigated whether Mtb may inhibit MHC class I expression by infected TGPMs. Mtb and TLR2 agonists inhibit IFN γ -induced MHC class II expression by bone marrow derived macrophages, and the mycobacterial PPE38 protein can inhibit MHC class I expression in RAW264.7 macrophages and TGPMs infected with *Mycobacterium smegmatis* [37, 38]. Therefore, we asked whether Mtb impaired MHC class I expression in our in vitro infection system, especially since the TGPMs were not pre-activated with IFN γ prior to infection. We measured MHC class I and II expression by macrophages on each of the five days following infection. At baseline, uninfected TGPMs expressed high MHC class I, and Mtb infection did not alter MHC class I expression compared to the baseline (Fig 6E and 6F; solid lines). IFN γ pretreatment of macrophages led to an increase in MHC class I expression by both uninfected and infected TGPMs, although the infected cells expressed slightly less MHC class I (Fig 6E and 6F; dotted lines). As expected, the regulation of MHC class II was more sensitive to IFN γ . Uninfected TGPMs expressed low baseline levels of MHC class II (Fig 6G and 6H; solid lines). IFN γ pretreatment resulted in a >100-fold increase in MHC class II median fluorescence intensity (MFI) in the uninfected TGPMs, which peaked on day 3 with a >2000-fold increase over the baseline (Fig 6G and 6H; dotted lines). Mtb-infection alone did not significantly affect MHC class II expression, and consistent with previous studies, Mtb significantly impaired the induction of MHC class II by IFN γ pretreatment (Fig 6G and 6H). These data show that, in our in vitro infection model where the TGPMs were unstimulated, Mtb infection did not inhibit class I and II MHC expression. Importantly, the differences in MHC class I or class II expression by Mtb-infected macrophages cannot explain why P25 T cells, but not TB10Rg3 T cells, recognized infected macrophages.

Macrophages cross-present antigens from non-viable Mtb to TB10.4-specific CD8⁺ T cells

Next, we hypothesized that Mtb may interfere with MHC class I presentation of mycobacterial antigens. Therefore, we tested the ability of the P25 and TB10Rg3 T cell lines to recognize TGPMs cultured with γ -irradiated, nonviable Mtb. Activation of pattern recognition receptors such as TLR2 and TLR4 by large amounts of dead bacteria might induce large amounts of IL-12 and IL-18, resulting in cytokine-driven T cell activation. Taking this concern into consideration, we used MHC-mismatched TGPMs as a control. We pulsed macrophages with a dose titration of γ -irradiated Mtb, then added TB10Rg3 or P25 T cells, and measured IFN γ secretion by the T cells after 72 hours. Both P25 and TB10Rg3 T cells produced high amounts of IFN γ when cultured with MHC-matched (i.e., H-2^b) but not with MHC-mismatched (i.e., H-2^k) TGPMs, and this response was dose dependent (Fig 6I and 6J). The ability of macrophages to process and present TB10.4 after phagocytosing γ -irradiated Mtb but not viable bacteria raises the possibility that live Mtb actively inhibit MHC class I presentation of TB10.4.




Fig 6. Probing potential mechanisms for lack of recognition by TB10Rg3 T cells. (a-c) EsxH (TB10.4) and its partner EsxG were overexpressed together in H37Rv to determine whether increasing TB10.4 abundance would lead to recognition of infected macrophages (esxGH-OE.Mtb). (a) Tetracycline treatment of esxGH-OE.Mtb in broth culture induces protein expression of EsxH (TB10.4) as measured by western blot. A different strain, fbpB-OE.Mtb, in which fbpB (e.g., Ag85b) is induced by tetracycline, does not result in greater EsxH (TB10.4) expression. Protein signal was normalized to that of GroEL2, a chaperonin protein. (b) Tetracycline treatment of esxGH-OE.Mtb in broth culture induces esxG and esxH, but not fbpB (which encodes for Ag85b) and sigA (which encodes for RNA polymerase factor sigma A), mRNA as measured by qPCR. Fold-induction was normalized to baseline (i.e., uninduced). IFN γ production by (c) P25 or (d) TB10Rg3 T cells after co-culture with macrophages infected with uninduced or induced esxGH-OE.Mtb. (e-h) MHC class I and II expression by Mtb infected-macrophages. Representative histograms (e) and fold-change (f) of MHC class I or representative histograms (g) and fold-change (h) of MHC class II expression on infected cells. (i) P25 and (j) TB10Rg3 production of IFN γ after co-culture with macrophages pulsed with titrated amounts of γ -irradiated (non-viable) H37Rv. Data is representative of 3 experiments. Statistical testing by one-way ANOVA with Dunnett posttest. *, $p < 0.05$; **, $p < 0.01$; and ***, $p < 0.005$.

<https://doi.org/10.1371/journal.ppat.1007060.g006>

Polyclonal, TB10.4_{4–11}-tetramer negative CD8⁺ T cells from the lungs of Mtb-infected mice recognize infected macrophages

Along with the previous finding that TB10.4_{4–11}-specific CD8⁺ T cells make up ~40% of total lung CD8⁺ T cells during infection (S5 Fig) [20], our finding that TB10Rg3 T cells do not recognize Mtb-infected macrophages suggests that TB10.4 may be a decoy antigen. This raises the question whether the inability to recognize Mtb-infected macrophages is a general feature of the CD8⁺ T cell response to Mtb, or if this is a unique feature of TB10.4-specific CD8⁺ T cells. Therefore, we determined whether polyclonal CD8⁺ T cells from the lungs of infected mice could recognize Mtb-infected macrophages. We carried out aerosol infection of C57BL/6 mice with Erdman, and, 6–8 weeks post infection, we purified polyclonal CD4⁺ or CD8⁺ T cells from their lungs and co-cultured them with Mtb-infected macrophages. After 72 hours of co-culture, polyclonal CD4⁺ T cells produced high amounts of IFN γ in a MHC-restricted manner (Fig 7A). Interestingly, polyclonal CD8⁺ T cells also produced IFN γ in a MHC-restricted manner when co-cultured with Mtb-infected macrophages (Fig 7B). Although the polyclonal CD8⁺ T cells were contaminated by less than the 1.5% CD4⁺ T cells, we conducted experiments using MHC I^{-/-} macrophages and showed that the polyclonal CD8⁺ T cells produced significant IFN γ only in the presence of MHC I was intact, excluding the possibility that the IFN γ production was due to contaminating CD4⁺ T cells and showing that the Mtb-specific CD8⁺ T cells were Kb or Db restricted (S6 Fig). These results indicate that other antigen-specific CD8⁺ T cells recognizing Mtb-infected macrophages do exist, and infected TGPMs can present Mtb antigens to CD8⁺ T cells. However, based on the high abundance of TB10.4-specific CD8⁺ T cells post infection (S5 Fig), the non-TB10.4-specific, Mtb-specific CD8⁺ T cells may be dwarfed by the dominant TB10.4-specific CD8⁺ T cells.

To better assess whether the IFN γ production by polyclonal CD8⁺ T cells arose predominantly from non-TB10.4-specific CD8⁺ T cells, we used the TB10.4_{4–11}-tetramer to separate TB10.4-specific and non-TB10.4-specific, polyclonal CD8⁺ T cells from the lungs of infected mice. After 72-hour co-culture with Mtb-infected macrophages, TB10.4_{4–11}-tetramer negative CD8⁺ (non-TB10.4-specific CD8⁺) T cells produced significantly higher IFN γ compared to that of uninfected control ($p < 0.005$), and the production was MHC class I restricted (Fig 7C). In contrast, TB10.4_{4–11}-specific CD8⁺ T cells produced IFN γ in a non-MHC-restricted manner during co-culture with both uninfected and Mtb-infected macrophages (Fig 7D). We cannot exclude the possibility that the tetramer isolation might have inadvertently activated the TB10.4_{4–11}-specific CD8⁺ T cells. Nevertheless, these data show that polyclonal, TB10.4_{4–11}-tetramer negative CD8⁺ T cells recognized Mtb-infected macrophages, supporting the notion of a subdominant T cell response that may be effective at detecting Mtb.




Fig 7. Polyclonal CD8⁺ T cells from the lungs of Mtb-infected mice recognize infected macrophages. IFN γ production by polyclonal CD4⁺ (a) or CD8⁺ (b) T cells after co-culture with either MHC-matched (H-2^b) or MHC-mismatched (H-2^k), Mtb-infected macrophages. IFN γ production by TB10.4₄₋₁₁-tetramer-depleted (c) or tetramer-enriched (d) polyclonal CD8⁺ T cells after co-culture with either MHC-matched (H-2^b) or MHC-mismatched (H-2^k), Mtb-infected macrophages. Data is representative of at least 2 experiments. Statistical testing by a two-tailed, unpaired Student's T test. *, p<0.05; **, p<0.01; and ***, p<0.005.

<https://doi.org/10.1371/journal.ppat.1007060.g007>

Discussion

A complexity in defining T cell recognition is distinguishing cognate from non-cognate recognition. T cell IFN γ production, a common readout for recognition, can be stimulated by IL-12 and IL-18, two cytokines secreted by Mtb-infected cells [27, 29–31]. Even cognate recognition does not always signify recognition of infected cells. Uninfected macrophages and dendritic cells (DCs) can acquire exosomes, soluble proteins, apoptotic vesicles or necrotic debris containing non-viable bacilli or its antigens, and present these to T cells [13, 39–41]. This detour pathway allows T cells to be activated by uninfected DCs [39, 42]. Thus, T cell recognition of infected macrophages, which is central to our fundamental paradigm of TB pathogenesis, remains poorly defined.

Our study advances the understanding of T cell recognition of Mtb-infected cells. By focusing on TCR-mediated recognition, our data show that T cells specific to immunodominant antigens vary in their ability to recognize Mtb-infected macrophages. Despite being a persistent and dominant population of CD8⁺ T cells in the lungs of Mtb-infected mice, TB10.4_{4–11}-specific CD8⁺ T cells do not recognize Mtb-infected macrophages. While we primarily used TGPMs, which have been used to model human macrophages [43, 44], we also showed that TB10.4-specific CD8⁺ T cells failed to recognize lung APCs from infected mice. Importantly, concurrent with our analysis of CD8⁺ T cells, we systematically assessed recognition of Mtb-infected macrophages by Ag85b-specific (i.e., P25) and ESAT-6-specific (i.e., C7) CD4⁺ T cells. Both recognized Mtb-infected macrophages and inhibited bacterial growth (here and [10]). Thus, under conditions that activated Mtb-specific CD4⁺ T cells, no activation of TB10.4-specific CD8⁺ T cells occurred. This finding has many implications, among which the most important is that not all Mtb-specific T cells recognize Mtb-infected macrophages.

These results led us to re-examine the evidence that CD8⁺ T cells recognize infected cells. In our evaluation of the literature, among the best evidence is: (1) direct *ex vivo* recognition of Mtb-infected macrophages and DC by CD4⁺ and CD8⁺ T cells [45–48]; (2) murine T cells' cytolytic activity (CTL) of Mtb-infected cells [49–51]; (3) human CD8⁺ T cells that recognize Mtb-infected DC [52–54]. However, these data have limitations. The murine studies never demonstrated cognate recognition, and the frequencies were lower than expected. The human studies only used DC and not macrophages and used a high MOI, raising concerns about death of infected cells and presentation of nonviable antigen. Nevertheless, these studies support the idea that CD8⁺ T cells recognize infected cells, but their frequency that recognize infected macrophages might be lower than we previously expected. Such a finding might explain why CD8⁺ T cells make a disproportionately small contribution to host defense, even though Mtb infection elicits a robust CD8⁺ T cell response.

We investigated several mechanisms that might explain why TB10.4-specific CD8⁺ T cells do not recognize infected macrophages. One possibility is the access of the TB10.4 antigen to the MHC class I processing pathway. Mtb can disrupt the phagosomal membrane and translocate into the cytosol [55], though this action often occurs later in infection and leads to necrosis of the macrophage [56]. We saw no evidence of recognition even at late time points such as days 4–5 post infection (Fig 3), when phagosomal disruption and bacterial translocation occurs [56]. The importance of antigen location became apparent during the *Listeria* infection experiments, where infected macrophages presented TB10.4_{4–11} only when the bacteria could enter the cytosol (i.e., Δ ActA.TB10 but not Δ LLO.TB10). The *Listeria* experiments also provided an additional insight. Lindenstrom et al report that vaccination with TB10.4 (EsxH), which has a leucine at position 12 (i.e., IMYNYPAML), inefficiently generates TB10.4-specific CD8⁺ T cells [57]. However, vaccination with TB10.3 (EsxR), a related antigen that also contains the same epitope followed by a methionine (i.e., IMYNYPAMM), elicits TB10.4-specific

CD8⁺ T cells. Based on that finding, they conclude there is a processing defect that prevents the generation of the TB10.4_{4–11} epitope from the TB10.4 protein. However, they also find that TB10.4-specific CD8⁺ T cells elicited by TB10.3 vaccination recognize splenocytes pulsed with the rTB10.4 proteins, showing that the full length TB10.4 protein can be processed and presented. These data indicate that the lack of vaccine-elicited TB10.4-specific CD8⁺ T cells is due to a problem with priming after vaccination instead of an inability to process the IMYNYPPAM epitope. Moreover, our data using TB10.4-expressing *Listeria* show that TGPMs can process the full length TB10.4 protein and present the TB10.4_{4–11} epitope. Therefore, we conclude that amino acid sequence of TB10.4 does not hinder its processing. The *Listeria* experiments also show the potential importance of antigen location and raise the possibility that sequestration of the TB10.4 antigen in the phagosome renders it inaccessible to the MHC class I presentation pathway.

Low antigen abundance could also explain the lack of recognition. We have previously argued that there is limited amount of TB10.4 antigen presentation in the lungs of infected mice, leading to extreme bias in the TCR repertoire of the TB10.4-specific CD8⁺ T cell response and defects in the memory-recall response in vivo [20, 24]. Importantly, bacterial TB10.4 levels are regulated by iron availability, and its expression varies in different growth medias [58]. Tinaztepe et al showed that, while H37Rv grown in 7H9 media reduced its TB10.4 expression in broth culture, the bacteria, during subsequent infection in BMDMs, required TB10.4 to remain virulent and survive in the BMDMs [58]. To test the possibility of low antigen abundance, we overexpressed EsxG and EsxH (TB10.4) together but did not see greater T cell recognition of Mtb-infected macrophages, suggesting that abundance might not be the issue.

Unexpectedly, macrophages pulsed with γ -irradiated Mtb were recognized by TB10.4-specific CD8⁺ T cells, raising the possibility that live Mtb actively inhibits MHC class I presentation of TB10.4. This is particularly interesting since the presentation of CFP10, another ESAT-6-like protein, by human DCs to CD8⁺ T cells requires viable Mtb; DCs given heat-killed bacteria do not present CFP10 to T cells [54]. While these data suggest that presentation requires active secretion of CFP10 [59, 60], the heat-killing process could have destroyed CFP10, or there might not have been sufficient amounts of CFP10 available in the non-viable bacteria. In combination with our data showing polyclonal CD8⁺ T cells recognize Mtb infected macrophages, these data show that it is possible that certain antigens are presented by live Mtb while others are actively prevented from being sampled by MHC class I. A caveat to these studies is the amount of TB10.4 present in the γ -irradiated bacteria could differ from the live bacteria because of differences in the culture conditions. The H37Rv used for γ -irradiation was grown in the Glycerol-Alanine-Salt (GAS) minimal media whereas the H37Rv used for all other experiments was grown in 7H9 media supplemented with OADC, Tween80 and glycerol. As both media contain iron (from the FBS in 7H9 media or from the ferric ammonium citrate in GAS media), and that iron is the key regulator of TB10.4 expression, we do not expect that differences in the culture media would interfere with the outcomes of the experiments.

Ag85b is an immunodominant antigen with an epitope recognized by CD4⁺ T cells in C57BL/6 mice. In vivo data shows that Ag85b-specific CD4⁺ T cells can recognize Mtb-infected cells early during infection; however, recognition decreases after infection is established [12, 14, 15, 61, 62]. The inability of Ag85b-specific CD4⁺ T cells to efficiently recognize Mtb-infected bone-marrow derived macrophages (BMDMs) or bone-marrow derived dendritic cells (BMDCs) stems from a combination of reduced Ag85b expression by Mtb and because infected cells actively export Ag85b into the extracellular milieu [12, 13]. In our experiments, we found that P25 T cells recognized Mtb-infected macrophages and inhibited bacterial growth in a MHC-restricted manner. A difference between the studies is the duration of macrophage and T cell co-culture. Grace et al examined 16–24 hours and found a

lack of recognition, whereas our assays focused on 72–96 hours and detected recognition. Moreover, it is unknown whether Mtb-infected cells still exported antigens after the initial 24 hours of infection. Furthermore, the exported Ag85b could be taken up by infected cells during longer co-cultures, leading to their recognition by T cells. Finally, it is possible that cognate recognition of uninfected cells that present Ag85b could activate CD4⁺ T cells in a TCR-mediated manner, inducing IFN γ and indirectly controlling Mtb replication in macrophages. Nonetheless, under conditions that activate Mtb-specific CD4⁺ T cells, we could not observe activation of TB10.4-specific CD8⁺ T cells.

The TB10.4_{4–11} epitope has been extensively used to characterize CD8⁺ T cell responses in the mouse model of TB, and TB10.4-specific CD8⁺ T cell responses have also been characterized in people with tuberculosis [20, 22, 24, 57, 63–65]. The finding that TB10.4-specific CD8⁺ T cells do not recognize infected macrophages was unexpected, particularly since TB10.4-specific CD8⁺ T cells persist in the lungs of infected mice and become more dominant with time [19, 20]. From these experiments, two questions warrant further investigation: 1) whether the CD8⁺ T cells specific to other epitopes of TB10.4 also inefficiently recognize infected macrophages, and 2) whether the species or the host genetic background influence recognition of infected cells.

In retrospect, our findings may partially explain why eliciting TB10.4-specific CD8⁺ T cells by vaccination fails to protect mice against Mtb infection [24, 57]. While vaccination with immunodominant antigens recognized by CD4⁺ T cells (e.g., Ag85b, ESAT-6) induce moderate protection [66, 67], we must consider the possibility that these antigens may not be the best stimulators of protective immunity. Ag85b-specific CD4⁺ T cells have variable efficacy, in large part due to its reduced expression by the bacterium as early as 3 weeks after infection [11, 12]. However, by their nature, the recruitment of memory T cell responses specific for immunodominant antigens is only incrementally faster than the primary T cell response [10, 24]. Thus, a crucial question for vaccine development is whether other Mtb antigens resemble TB10.4, in that they elicit T cell responses that fail to recognize infected macrophages. We did detect polyclonal CD8⁺ T cells that recognized Mtb infected macrophages, corroborating a previous study showing that polyclonal CD8⁺ T cells from infected mice can lyse Mtb-infected cells [49]. These data indicate that there are antigens presented by Mtb-infected cells, even if those antigens may be subdominant compared to TB10.4. Thus, future vaccine developments will benefit by identifying antigen targets based on their ability of being presented rather than only their immunogenicity.

Priming of TB10.4-specific CD8⁺ T cells occurs early after Mtb infection in the lung draining lymph node (LN) [24, 68]. Yet it is unknown whether priming of naïve T cells occurs via Mtb-infected DCs, or uninfected DCs that acquire antigen through uptake of apoptotic blebs containing Mtb proteins [39, 42], or by the transfer of antigen from cell to cell [41]. Priming by an uninfected cell can have detrimental consequences if the infected cell presents a different repertoire of Mtb antigens. Considering our findings, we propose that TB10.4 is a decoy antigen: TB10.4-specific CD8⁺ T cells expand in the LN during priming, accumulate in the lungs, but ineffectively recognize Mtb-infected macrophages. This raises the hypothesis that not all immune responses elicited by Mtb provide benefits to the host. Interestingly, Mtb genes encoding epitopes recognized by T cells are more highly conserved than other DNA elements, implying that T cell recognition of these Mtb epitopes may provide a survival advantage to the bacterium [69, 70]. For example, T cell dependent inflammation may benefit Mtb by promoting transmission. Even though TB10.4 is more variable than most other antigens, our results support these genetic data [69, 70]. Thus, Mtb focuses the CD8⁺ T cell response on the decoy antigen TB10.4 and distracts the immune response from other antigens that might be targets of protective immunity, successfully evading T cell immunity and enabling it to establish itself

as persistent infection. Although we do not yet know whether the phenomenon we have described for TB10.4 will be true for other antigens, our data do reveal the hazards of selecting vaccine antigens based on immunogenicity and immunodominance alone. We propose that greater consideration should be given for the ability vaccine antigens to elicit T cells that recognize infected cells.

Materials and methods

Ethics statement

Studies involving animals were conducted following relevant guidelines and regulations, and the studies were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts Medical School (Animal Welfare A3306-01), using the recommendations from the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the Office of Laboratory Animal Welfare.

Mice

C57BL/6J, Rag-1-deficient (B6.129S7-Rag1^{tm1Mom}), B10 (C57BL/10J), B10.BR (B10.BR-H2^{k2}H2-T18^a/SgSnJrep), P25 (C57BL/6-Tg(H-2K^b-Tcr α ,Tcr β)P25Ktk/J) [25, 71], mice were obtained from Jackson Laboratories (Bar Harbor, ME). C57BL/6J and B10 mice were used for isolating MHC-matched TGPMs while B10.BR mice were used for isolating MHC-mismatched TGPMs. C57BL/6 K^b-D^b- (MHC I^{-/-}) mice were a generous gift from Dr. Kenneth Rock (University of Massachusetts Medical School, MA). C7 TCR transgenic mice were a generous gift from Dr. Eric Pamer (Memorial Sloan Kettering Cancer Center, NY)[35].

Thioglycolate-elicited peritoneal macrophages

Thioglycolate-elicited peritoneal macrophages were obtained 4–5 days after intra-peritoneal injection of mice with 3% thioglycolate solution, as described [29]. 1×10^5 macrophages were plated per well. Macrophages were maintained in culture with RPMI 1640 media (Invitrogen Life Technologies, ThermoFisher, Waltham, MA) supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine (all from Invitrogen Life Technologies) and 10% heat-inactivated fetal bovine serum (HyClone, GE Healthcare Life Sciences, Pittsburgh, PA), referred hereafter as supplemented complete media.

Generation of CD8⁺ and CD4⁺ T cell lines

Retrogenic mice expressing TB10Rg3 TCR specific for the TB10.4_{4–11} epitope were generated as previously described [20]. The TB10Rg3 CD8⁺ T cells were isolated from these mice, stimulated *in vitro* with irradiated splenocytes pulsed with the peptide TB10.4_{4–11} in complete media containing IL-2. P25 or C7 CD4⁺ T cells were isolated from transgenic P25 or C7 mice, respectively [25, 35]. The P25 and C7 cells were stimulated *in vitro* with irradiated splenocytes pulsed with the Ag85b_{240–254} peptide or the ESAT-6_{3–17}, respectively, in complete media containing IL-2 and anti-IL-4. After the initial stimulation, these T cells were split every two days for 3–4 divisions and rested for two to three weeks. After the initial stimulation, the cells were cultured in complete media containing IL-2 and IL-7.

Peptides

The following synthetic peptide epitopes were used as antigens: TB10.4_{4–11} (IMYNYPAM); Ag85b_{240–254} (FQDAYNAAGGHNAVF); and ESAT-6_{3–17} (EQQWNFAGIEAAASA). We also

generated a negative control peptide predicted to not bind to H-2 K^b: IMANAPAM. The peptides were obtained from New England Peptides (Gardner, MA).

As positive controls for assessing the function of macrophages to present antigen, uninfected macrophages and, in certain experiments, infected macrophages were pulsed with the peptides of interest. We pulsed macrophages by incubating 10 μ M of the peptides of interest with the macrophages in supplemented complete RPMI 1640 media for 1 hour. After incubation, the cells were washed 3 to 5 times with fresh supplemented complete RPMI 1640 media. The cells were then resuspended in supplemented complete RPMI 1640 media for experiments.

***In vitro* Mtb infection**

H37Rv was grown as previously described [29]. Bacteria was grown in BD Difco Middlebrook 7H9 (Thermo Fisher, Waltham, MA) supplemented with 10% OADC (Sigma-Aldrich, St. Louis, MO), 0.2% glycerol and 0.05% Tween-80 (both from Thermo Fisher) to an OD₆₀₀ of 0.6–1.0, washed in RPMI, opsonized with TB coat (RPMI 1640, 1% heat-inactivated FBS, 2% human serum, 0.05% Tween-80), washed again and filtered through a 5 micron filter to remove bacterial clumps. The bacteria were counted using a Petroff-Hausser chamber. Infection was performed as previously described [29]. The final multiplicity of infection (MOI), based on plating CFU, was 0.2–0.8 for all experiments, unless otherwise indicated. For CFU-based, bacterial growth inhibition assays, T cells were added at a ratio of 5 T cells to each macrophage. Four replicate wells were used for each condition. Cell cultures were lysed by adding 1/10th volume of 10% Triton X-100 in PBS (final concentration of 1%), and CFUs were determined by plating in serial dilutions of the lysates on Middlebrook 7H10 plates (Hardy Diagnostics, Santa Maria, CA). CFUs were enumerated after culture for 21 days at 37°C and 5% CO₂.

***In vivo* aerosol Mtb infection and lung cell isolation**

Aerosol infection of mice was done with the Erdman strain of Mtb using a Glas-Col aerosol-generation device. A bacterial aliquot was thawed, sonicated for 1 minute and then diluted in 0.9% NaCl-0.02% Tween-80 to 5 ml. The number of Mtb deposited in the lungs was determined for each experiment, by plating undiluted lung homogenate from a subset of the infected mice within 24 hours of infection. The inoculum varied between 37–120 CFU. For the ex vivo APC experiments, lung cells were isolated from Erdman-infected, RAG-1-deficient mice, 4-weeks post-infection, and the APCs were enriched by positive selection using anti-MHC class II⁺ microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and the Miltenyi AutoMACS. On average, the isolated cells were 89% CD11c⁺ or CD11c⁺CD11b⁺. The APCs were counted on a hemocytometer and plated at 1x10⁵ per well in supplemented complete RPMI 1640 media.

For the ex vivo CD4⁺ and CD8⁺ T cell experiments, single cell suspensions were isolated from the lungs of infected C57BL/6 mice, 6 to 8 weeks post-infection, as described [10]. Polyclonal CD4⁺ and CD8⁺ T cells were enriched by positive selection using Mouse CD4⁺ and Mouse CD8⁺ T cell isolation kits, respectively (Miltenyi Biotec). After enrichment, average purity for polyclonal CD4⁺ and CD8⁺ T cells were 93% and 95%, respectively. For experiments investigating TB10.4₄₋₁₁-tetramer positive cells and polyclonal, non-TB10.4-specific, CD8⁺ T cells, the following isolation was done. Single cell suspensions from the lungs of infected mice were incubated with APC-conjugated, TB10.4₄₋₁₁-loaded, H-2^b tetramers from the National Institute of Health Tetramer Core Facility (Emory University Vaccine Center, Atlanta, GA). Tetramer positive CD8⁺ T cells were then selected via the AutoMACS separator by anti-APC microbeads (Miltenyi Biotec). Average purity of TB10.4₄₋₁₁-tetramer positive, CD8⁺ T cells

was 85%, with 1.4% contaminating CD4⁺ T cells. The tetramer negative population was subsequently washed and then enriched for polyclonal CD8⁺ T cells via Mouse CD8⁺ T cell isolation kit (Miltenyi Biotec). Average purity of polyclonal, non-TB10.4₄₋₁₁-tetramer positive, CD8⁺ T cells was 75% with 0.8% contaminating CD4⁺ T cells and 13% contaminating TB10.4₄₋₁₁-tetramer positive CD8⁺ T cells. The T cells were counted using a hemocytometer and resuspended in supplemented complete RPMI 1640 media before being used in experiments.

Listeria infections

The recombinant *Listeria* strains have been previously described [24]. For in vitro infections, they were grown to an OD₆₀₀ of 0.6–1.0 in BHI media (Sigma Aldrich) with 10 µg/ml chloramphenicol (Sigma Aldrich) at 30°C. Macrophages were infected with the *Listeria* strains using a MOI 50, for 45 minutes. Extracellular bacteria were eliminated by adding 60 µg/ml gentamicin (Sigma Aldrich) for 20 minutes. Bacterial burden was assessed by lysing the infected macrophages with 1% TritonX-100 in PBS, and plating serial dilutions of the lysate on BHI agarose supplemented with 10 µg/ml chloramphenicol (Sigma Aldrich, St. Louis, MO). Recombinant listeriolysin (Prospec, East Brunswick, NJ) was added in some experiments at 2 µg/ml for 30 minutes, and any excess was washed away. Bafilomycin (InvivoGen, San Diego, CA) was added in some experiments at 5 µM for 30 minute, before being washed away.

Generation of TB10.4-overexpressing Mtb strains

pJR1103 was cleaved with EcoRI-HF and Sall-HF [72]. mCherry preceded by the groEL2 promoter from H37Rv was inserted by HiFi Assembly. The resulting plasmid was cleaved with NdeI and NotI-HF. The *esxGH* gene from H37Rv, along with 12 upstream nucleotides, was inserted by HiFi Assembly following the plasmid-borne tetracycline-inducible promoter. All enzymes used above were purchased from New England Biolabs. The resulting plasmid (pGB6) was electroporated into Mtb H37Rv and integrated at the L5 site. RNA was purified from induced and uninduced cultures using TRIzol (ThermoFisher) and chloroform extraction, followed by purification on Zymo columns. cDNA was produced with Superscript IV (ThermoFisher), and quantitative PCR was performed using the iTaq SYBR Green Supermix (Bio-Rad, Hercules, CA) on an Applied Biosystems Viia 7 thermocycler.

For confirmation of overexpression of TB10.4 (*esxH*), western blot was performed. Strains were induced in mid log phase with anhydrotetracycline (ATc) for 24 hours. Bacterial pellets were washed and resuspended in PBS + protease inhibitor, then heat-inactivated for 2h @ 80–90°C and lysed by bead beating. Lysates were clarified by centrifugation and separated by electrophoresis (~2 µg protein per lane). Proteins were transferred onto nitrocellulose and probed with primary antibodies against TB10.4 (*esxH*) at 1:400 concentration (Antibodies-Online, Atlanta, GA) and GroEL2 (Hsp60/65) at 1:1000 concentration (GeneTex, Irving, CA). Anti-rabbit 680 (for *esxH*) and anti-mouse 800 (for GroEL2) were used at 1:15,000 concentration (both from LI-COR Biosciences, Lincoln, NE). PageRuler Plus Prestained (ThermoFisher) protein ladder was used. Antibody incubations were done in MB-070 blocking buffer (Rockland, Limerick, PA). Infrared detection was done on a LI-COR Odyssey CLx. Quantification was performed using LI-COR ImageStudio software. Strain *fbpB.OE-Mtb* is a Mtb strain made to overexpress *fbpB* (Ag85b) protein and acts as a specificity control as ATc treatment of this strain is not expected to increase the TB10.4 protein.

Irradiated H37Rv

The following reagent was obtained through BEI Resources, NIAID, NIH: *Mycobacterium tuberculosis*, Strain H37Rv, Gamma-Irradiated Whole Cells, NR-14819. The irradiated H37Rv

was gently sonicated using a cup-horn sonicator at a low power to disperse bacterial clumps while limiting bacterial lysis. The number of bacteria, or antigen load, was approximated by measuring the turbidity at OD₆₀₀, and correlating it with live H37Rv (OD₆₀₀ = 1 is equivalent to 3.0x10⁸ CFU/ml). To pulse TGPMS, diluted, sonicated, γ -irradiated H37Rv were added to adherent macrophages for one hour before repeatedly washing the cultures to remove residual extracellular bacteria. Subsequently, TB10Rg3 or P25 T cells were added at a ratio of 1 T cell to 1 macrophages. After 72 hours, the amount of IFN γ in the supernatants was measured using Mouse IFN γ ELISA MAX kits (Biolegend, San Diego, CA).

Flow cytometry analysis

The following cell surface antigens were detected by flow cytometry using the following antibodies: mouse CD4 (clone GK1.5), CD8 (clone 53–6.7), CD3 ϵ (clone 145-2C11), CD69 (clone H1.2F3), I-A/I-E (clone M5/114.15.2), and H-2K^b (clone AF6-88.5) (all from Biolegend). BV421- and APC-conjugated, TB10.4_{4–11}-loaded, H-2K^b tetramers were obtained from the National Institutes of Health Tetramer Core Facility (Emory University Vaccine Center, Atlanta, GA). Zombie Violet Fixable viability dye (Biolegend) or the Live/Dead Fixable Far Red Dead Cell stain (ThermoFisher) were used for distinguishing live from dead cells. To stain for the Nur77 transcription factor, the Nur77 monoclonal antibody (clone 12.14) was used in combination with the Foxp3 Transcription Factor Staining Buffer Set (both from ThermoFisher) by the manufacturer's protocol. Live/dead viability staining and surface staining were done for 20 minutes at 4°C, and intracellular staining was done for 30 minutes at room temperature. Samples were then fixed with 1% paraformaldehyde/PBS for 1 hour before being analyzed by a MACSQuant flow cytometer (Miltenyi Biotec). FlowJo Software (Tree Star, Portland, OR) was used to analyze the collected data. Single lymphocytes were gated by forward scatter versus height and side scatter for size and granularity, and dead cells were excluded.

Normalization and statistical analysis

To compare the cellular expression of Nur77 and CD69 expression levels between time points, the MFI values were normalized as follows: experimental values were divided by the difference between the isotype control MFI (minimum response) and the peptide control MFI (maximum response).

Each figure represents a minimum of 2 similar experiments, with 2 to 4 biological replicates in each experiment. Data are represented as mean \pm standard error of the mean (SEM). For comparing two groups, a two-tailed, unpaired student's t-test was used. For more than two groups, the data were analyzed using a one-way ANOVA. A p value < 0.05 was considered to be statistically significant. Analysis was performed using GraphPad Prism, Ver. 7 (GraphPad Software, La Jolla, CA).

Supporting information

S1 Fig. P25 T cells specifically respond to specifically to the Ag85b₂₄₀₋₂₅₄ epitope. MHC-matched (H-2^b) and MHC-mismatched (H-2^k) macrophages were pulsed with 10 μ M of Ag85b₂₄₀₋₂₅₄ or TB10.4_{4–11} synthetic peptides. After 1 hour, unbound peptides were washed out, and P25 T cells were added for 72 hours. Induction of CD69 was measured by flow cytometry and IFN γ was measured by ELISA. The normalized CD69 MFI (a) and IFN γ (b) produced by P25 T cells were measured. Data representative of 3 experiments. (PDF)

S2 Fig. TCR analysis and cloning of TCRs expressed by TB10.4₄₋₁₁-specific CD8⁺ T cells from the lungs of Mtb-infected C57BL/6 mice. Mononuclear lung cells were obtained from three individual C57BL/6 mice, 9 weeks after low-dose aerosol infection with Mtb Erdman. Single TB10.4₄₋₁₁-tetramer⁺ CD8⁺ T cells from each mouse were sorted into 96-well plates and the CDR3 α and CDR3 β sequences determined as described [20]. The analysis of a representative mouse is shown, for which 141 CDR3 α sequences was determined. A clonal expansion of TB10.4₄₋₁₁-tetramer⁺ CD8⁺ T cells, as previously described [20], was suggested by the skewed distribution of TRAV and TRAJ families (a), which shows an extreme bias in the use of TRAV7 and TRAJ15 gene segments, as well as a dominant CDR3 α amino acid (aa) length of 12 (b). (c) Analysis of all CDR3 α aa sequence with a length of 12 (n = 112) identify a consensus motif of CAVSGGGRALIF for TB10.4₄₋₁₁-specific CD8⁺ T cells. Amplification of CDR3 α and CDR3 β sequences from the same well allowed pairing of TCR α and TCR β for individual TB10.4₄₋₁₁-specific CD8⁺ T cells. Three individual mice were analyzed in this manner (d). We identified an expanded CDR3 β sequence containing the “xDRENSD” motif, the same motif that had been previously defined by NexGen sequencing [20]. Thus, mouse L1 had an expansion of CD8⁺ T cells with the CASSLDRENDYTF CDR3 β sequence, mouse L2 was dominated by CD8⁺ T cells using the CDR3 β sequence CASSQDRENDYTF, and mouse L3 expressed two major expansions, one encoding CASSLDRENDYTF and the other, CASSDDRENDYTF (d). Based on our ability to pair the CDR3 α and CDR3 β sequences, we detected an interesting reciprocal conservation. Namely, the ‘xDRENSD’ CDR3 β motif was matched to a ‘SxGGRA’ CDR3 α motif (e). Finally, we identified an expansion of a T cell clone in mouse L1, which expressed a novel sequence that we had not previously observed (i.e., CASSPDRGNTGQLYF) (d, e). Thus, with a high degree of confidence, we paired the CDR3 α and CDR3 β sequences belonging to 5 distinct TB10.4₄₋₁₁-specific CD8⁺ T cell clones that had been expanded in lungs of Mtb-infected C57BL/6 mice. The TCR α and TCR β cDNAs were reconstructed and cloned using standard methods, and retrogenic mice were subsequently produced [20, 73, 74]. (PDF)

S3 Fig. Reconstitution and expression of specific TCRs in C57BL/6 retrogenic mice. Retrogenic mice were produced as previously described [20]. Six weeks after retroviral transduction of bone marrow and reconstitution of congenically marked recipient mice, the expression of the recombinant TCR was determined in peripheral blood. (a) The BW58 α β ⁻ cell line was transduced with different retroviral constructs. GFP⁺ cells were sorted three times, and mAbs specific for V α or V β were used to confirm successful TCR expression and pairing of TB10RgP and TB10RgLD. The TB10Rg3 construct was included as internal control. (b) Representative flow cytometry plots showed gating strategy of donor-derived GFP⁺ specific V β ⁺ TB10.4₄₋₁₁-tetramer⁺ CD8⁺ TB10RgR and TB10RgLD mice. (c) Representative flow cytometry plots of splenic T cells from TB10RgP retrogenic mice demonstrating CD8⁺GFP⁺ T cells staining with the TB10.4₄₋₁₁-tetramer. (PDF)

S4 Fig. TB10Rg3 CD8 T cells do not recognize macrophages infected at high MOI. To determine whether a higher MOI would lead to more TB10 antigen production and presentation to TB10Rg3 CD8 T cells, TGPMs were infected with H37Rv at high MOI (average effective MOI of 1.65 to 5.98). TB10Rg3 T cells were added on d1 and d2 post infection for 2 hours, and their expression of Nur77 (a) and CD69 (b) were quantified. Data representative of at least 2 experiments for each time point. (PDF)

S5 Fig. TB10.4₄₋₁₁-tetramer positive CD8⁺ dominates the pulmonary CD8⁺ T cell response during Mtb infection in C57BL/6 mice. Representative flow plot showing the percent of TB10.4₄₋₁₁-tetramer positive CD8⁺ T cells among lung cells isolated from mice infected with Mtb Erdman via the aerosol route 6 weeks post-infection. Total lung mononuclear cells were stained with antibodies and tetramers and analyzed by flow cytometry. Lymphocytes were gated based on forward and side scatter and doublets were excluded. CD8 cells were distinguished from CD4 cells. TB10.4-tetramer⁺ CD8s were identified among the CD8 cell population.

(PDF)

S6 Fig. Polyclonal CD8⁺ T cells recognition of Mtb-infected macrophages requires MHC I expression. Polyclonal CD8⁺ T cells were purified from the lungs of C57BL/6J mice, and immediately cultured with either WT (H-2^b mφ) or K^bD^{b-/-} (MHC I^{-/-} mφ). After 72 hours, IFNγ in the cultures was measured by ELISA. Data is representative of 2 experiments. Statistical testing by a two-tailed, unpaired Student's T test. *, p<0.05; **, p<0.01; and ***, p<0.005.

(PDF)

Acknowledgments

We would like to thank Dr. Kenneth Rock (University of Massachusetts Medical School, MA) for the generous gift of C57BL/6 K^{b-/-}D^{b-/-} (MHC I^{-/-}) mice. We thank Barry Kriegsman for critical reading of the manuscript. We also thank the Animal Medicine team at University of Massachusetts Medical School (Worcester, MA) for their technical assistance.

Author Contributions

Conceptualization: Jason D. Yang, Jinhee Lee, Steve M. Carpenter, Samuel M. Behar.

Formal analysis: Jason D. Yang, Samuel M. Behar.

Funding acquisition: Samuel M. Behar.

Investigation: Jason D. Yang, Daniel Mott, Rujapak Sutiwisesak, Yu-Jung Lu, Fiona Raso, Britni Stowell, Jinhee Lee, Steve M. Carpenter.

Project administration: Samuel M. Behar.

Resources: Greg Hunter Babunovic, Sing Sing Way, Sarah M. Fortune.

Supervision: Sarah M. Fortune, Samuel M. Behar.

Writing – original draft: Jason D. Yang, Rujapak Sutiwisesak, Samuel M. Behar.

Writing – review & editing: Jason D. Yang, Daniel Mott, Yu-Jung Lu, Fiona Raso, Britni Stowell, Greg Hunter Babunovic, Jinhee Lee, Steve M. Carpenter, Sing Sing Way, Sarah M. Fortune, Samuel M. Behar.

References

1. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. *Current Opinion in Immunology*. 2003; 15(4):450. [https://doi.org/10.1016/s0952-7915\(03\)00075-x](https://doi.org/10.1016/s0952-7915(03)00075-x) PMID: 12900278
2. Orme IM. Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects. *Tuberculosis (Edinb)*. 2016. <https://doi.org/10.1016/j.tube.2014.10.008> PMID: 25500316.
3. Behar SM, Carpenter SM, Booty MG, Barber DL, Jayaraman P. Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. *Semin Immunol*. 2014; 26(6):559–77. Epub 2014/10/15. <https://doi.org/10.1016/j.smim.2014.09.003> PMID: 25311810; PubMed Central PMCID: PMC4250436.

4. Mogue T, Goodrich ME, Ryan L, LaCourse R, North RJ. The Relative Importance of T Cell Subsets in Immunity and Immunopathology of Airborne Mycobacterium tuberculosis Infection in Mice. *The Journal of Experimental Medicine*. 2001; 193(3):271–80. <https://doi.org/10.1084/jem.193.3.271> PMID: [11157048](https://pubmed.ncbi.nlm.nih.gov/11157048/)
5. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. Tuberculosis and HIV co-infection. *PLoS Pathog*. 2012; 8(2):e1002464. Epub 2012/03/01. <https://doi.org/10.1371/journal.ppat.1002464> PMID: [22363214](https://pubmed.ncbi.nlm.nih.gov/22363214/); PubMed Central PMCID: [PMCPMC3280977](https://pubmed.ncbi.nlm.nih.gov/PMC3280977/).
6. Ginsberg AM, Ruhwald M, Mearns H, McShane H. TB vaccines in clinical development. *Tuberculosis*. 2016; 99:S16–S20. <https://doi.org/10.1016/j.tube.2016.05.013> PMID: [27470538](https://pubmed.ncbi.nlm.nih.gov/27470538/)
7. Lindestam Arlehamn CS, Lewinsohn D, Sette A, Lewinsohn D. Antigens for CD4 and CD8 T cells in tuberculosis. *Cold Spring Harb Perspect Med*. 2014; 4(7):a018465. Epub 2014/05/24. <https://doi.org/10.1101/cshperspect.a018465> PMID: [24852051](https://pubmed.ncbi.nlm.nih.gov/24852051/); PubMed Central PMCID: [PMCPMC4066646](https://pubmed.ncbi.nlm.nih.gov/PMC4066646/).
8. Pai M, Riley LW, Colford JM. Interferon- γ assays in the immunodiagnosis of tuberculosis: a systematic review. *The Lancet Infectious Diseases*. 2004; 4(12):761–76. [https://doi.org/10.1016/S1473-3099\(04\)01206-X](https://doi.org/10.1016/S1473-3099(04)01206-X) PMID: [15567126](https://pubmed.ncbi.nlm.nih.gov/15567126/)
9. Srivastava S, Ernst JD. Cutting edge: Direct recognition of infected cells by CD4 T cells is required for control of intracellular Mycobacterium tuberculosis in vivo. *J Immunol*. 2013; 191(3):1016–20. Epub 2013/07/03. <https://doi.org/10.4049/jimmunol.1301236> PMID: [23817429](https://pubmed.ncbi.nlm.nih.gov/23817429/); PubMed Central PMCID: [PMCPMC3725655](https://pubmed.ncbi.nlm.nih.gov/PMC3725655/).
10. Carpenter SM, Yang JD, Lee J, Barreira-Silva P, Behar SM. Vaccine-elicited memory CD4+ T cell expansion is impaired in the lungs during tuberculosis. *PLoS Pathog*. 2017; 13(11):e1006704. Epub 2017/11/28. <https://doi.org/10.1371/journal.ppat.1006704> PMID: [29176787](https://pubmed.ncbi.nlm.nih.gov/29176787/).
11. Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. *Cell Host Microbe*. 2017; 21(6):695–706 e5. <https://doi.org/10.1016/j.chom.2017.05.012> PMID: [28618268](https://pubmed.ncbi.nlm.nih.gov/28618268/); PubMed Central PMCID: [PMCPMC5533182](https://pubmed.ncbi.nlm.nih.gov/PMC5533182/).
12. Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. *PLoS Pathog*. 2011; 7(5):e1002063. Epub 2011/06/04. <https://doi.org/10.1371/journal.ppat.1002063> PMID: [21637811](https://pubmed.ncbi.nlm.nih.gov/21637811/); PubMed Central PMCID: [PMCPMC3102708](https://pubmed.ncbi.nlm.nih.gov/PMC3102708/).
13. Srivastava S, Grace PS, Ernst JD. Antigen Export Reduces Antigen Presentation and Limits T Cell Control of M. tuberculosis. *Cell Host Microbe*. 2016; 19(1):44–54. Epub 2016/01/15. <https://doi.org/10.1016/j.chom.2015.12.003> PMID: [26764596](https://pubmed.ncbi.nlm.nih.gov/26764596/); PubMed Central PMCID: [PMCPMC4715867](https://pubmed.ncbi.nlm.nih.gov/PMC4715867/).
14. Lai R, Jeyanathan M, Afkhami S, Zganiacz A, Hammill JA, Yao Y, et al. CD11b(+) Dendritic Cell-Mediated Anti-Mycobacterium tuberculosis Th1 Activation Is Counterregulated by CD103(+) Dendritic Cells via IL-10. *J Immunol*. 2018. Epub 2018/01/28. <https://doi.org/10.4049/jimmunol.1701109> PMID: [29374077](https://pubmed.ncbi.nlm.nih.gov/29374077/).
15. Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, Germain RN. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. *Immunity*. 2011; 34(5):807–19. <https://doi.org/10.1016/j.immuni.2011.03.022> PMID: [21596592](https://pubmed.ncbi.nlm.nih.gov/21596592/)
16. Serafini A, Pisu D, Palu G, Rodriguez GM, Manganelli R. The ESX-3 secretion system is necessary for iron and zinc homeostasis in Mycobacterium tuberculosis. *PLoS One*. 2013; 8(10):e78351. Epub 2013/10/25. <https://doi.org/10.1371/journal.pone.0078351> PMID: [24155985](https://pubmed.ncbi.nlm.nih.gov/24155985/); PubMed Central PMCID: [PMCPMC3796483](https://pubmed.ncbi.nlm.nih.gov/PMC3796483/).
17. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. *PLoS Pathog*. 2011; 7(9):e1002251. Epub 2011/10/08. <https://doi.org/10.1371/journal.ppat.1002251> PMID: [21980284](https://pubmed.ncbi.nlm.nih.gov/21980284/); PubMed Central PMCID: [PMCPMC3182942](https://pubmed.ncbi.nlm.nih.gov/PMC3182942/).
18. Tufariello JM, Chapman JR, Kerantzas CA, Wong KW, Vilcheze C, Jones CM, et al. Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence. *Proc Natl Acad Sci U S A*. 2016; 113(3):E348–57. Epub 2016/01/06. <https://doi.org/10.1073/pnas.1523321113> PMID: [26729876](https://pubmed.ncbi.nlm.nih.gov/26729876/); PubMed Central PMCID: [PMCPMC4725510](https://pubmed.ncbi.nlm.nih.gov/PMC4725510/).
19. Woodworth JS, Shin D, Volman M, Nunes-Alves C, Fortune SM, Behar SM. Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination. *J Immunol*. 2011; 186(3):1627–37. Epub 2010/12/24. <https://doi.org/10.4049/jimmunol.1002911> PMID: [21178003](https://pubmed.ncbi.nlm.nih.gov/21178003/); PubMed Central PMCID: [PMCPMC3133636](https://pubmed.ncbi.nlm.nih.gov/PMC3133636/).
20. Nunes-Alves C, Booty MG, Carpenter SM, Rothchild AC, Martin CJ, Desjardins D, et al. Human and Murine Clonal CD8+ T Cell Expansions Arise during Tuberculosis Because of TCR Selection. *PLoS Pathog*. 2015; 11(5):e1004849. Epub 2015/05/07. <https://doi.org/10.1371/journal.ppat.1004849> PMID: [25945999](https://pubmed.ncbi.nlm.nih.gov/25945999/); PubMed Central PMCID: [PMCPMC4422591](https://pubmed.ncbi.nlm.nih.gov/PMC4422591/).

21. Skjot RLV, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff THM, et al. Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the *esat-6* Gene Family. *Infection and Immunity*. 2002; 70(10):5446–53. <https://doi.org/10.1128/IAI.70.10.5446-5453.2002> PMID: 12228269
22. Skjot RLV, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, et al. Comparative Evaluation of Low-Molecular-Mass Proteins from *Mycobacterium tuberculosis* Identifies Members of the *ESAT-6* Family as Immunodominant T-Cell Antigens. *Infection and Immunity*. 2000; 68(1):214–20. <https://doi.org/10.1128/iai.68.1.214-220.2000> PMID: 10603390
23. Lewinsohn DA, Swarbrick GM, Park B, Cansler ME, Null MD, Toren KG, et al. Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. *NPJ Vaccines*. 2017; 2(1). <https://doi.org/10.1038/s41541-017-0008-6> PMID: 28775896; PubMed Central PMCID: PMC5538316.
24. Carpenter SM, Nunes-Alves C, Booty MG, Way SS, Behar SM. A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during Tuberculosis. *PLoS Pathog*. 2016; 12(1):e1005380. Epub 2016/01/09. <https://doi.org/10.1371/journal.ppat.1005380> PMID: 26745507; PubMed Central PMCID: PMC4706326.
25. Tamura T, Ariga H, Kinashi T, Uehara S, Kikuchi T, Nakada M, et al. The role of antigenic peptide in CD4+ T helper phenotype development in a T cell receptor transgenic model. *Int Immunol*. 2004; 16(12):1691–9. Epub 2004/10/13. <https://doi.org/10.1093/intimm/dxh170> PMID: 15477229.
26. Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. *J Exp Med*. 2011; 208(6):1279–89. Epub 2011/05/25. <https://doi.org/10.1084/jem.20110308> PMID: 21606508; PubMed Central PMCID: PMC3173240.
27. Bastidas S, Graw F, Smith MZ, Kuster H, Gunthard HF, Oxenius A. CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals. *J Immunol*. 2014; 192(4):1732–44. Epub 2014/01/22. <https://doi.org/10.4049/jimmunol.1302027> PMID: 24446519.
28. Mariani F, Cappelli G, Riccardi G, Colizzi V. *Mycobacterium tuberculosis* H37Rv comparative gene-expression analysis in synthetic medium and human macrophage. *Gene*. 2000. PMID: 10940566.
29. Rothchild AC, Jayaraman P, Nunes-Alves C, Behar SM. iNKT cell production of GM-CSF controls *Mycobacterium tuberculosis*. *PLoS Pathog*. 2014; 10(1):e1003805. Epub 2014/01/07. <https://doi.org/10.1371/journal.ppat.1003805> PMID: 24391492; PubMed Central PMCID: PMC3879349.
30. Okamoto I, Kohno K, Tanimoto T, Ikegami H, Kurimoto M. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. *J Immunol*. 1999; 162(6):3202–11. Epub 1999/03/27. PMID: 10092771.
31. Akdis M, Burgler S, Cramer R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. *J Allergy Clin Immunol*. 2011; 127(3):701–21 e1-70. Epub 2011/03/08. <https://doi.org/10.1016/j.jaci.2010.11.050> PMID: 21377040.
32. Srivastava S, Ernst JD, Desvignes L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. *Immunological Reviews*. 2014; 262(1):179–92. <https://doi.org/10.1111/imr.12217> PMID: 25319335
33. Skold M, Behar SM. Tuberculosis Triggers a Tissue-Dependent Program of Differentiation and Acquisition of Effector Functions by Circulating Monocytes. *The Journal of Immunology*. 2008; 181(9):6349–60. <https://doi.org/10.4049/jimmunol.181.9.6349> PMID: 18941226
34. Gonzalez-Juarrero M, Shim TS, Kipnis A, Junqueira-Kipnis AP, Orme IM. Dynamics of Macrophage Cell Populations During Murine Pulmonary Tuberculosis. *The Journal of Immunology*. 2003; 171(6):3128–35. <https://doi.org/10.4049/jimmunol.171.6.3128> PMID: 12960339
35. Gallegos AM, Pamer EG, Glickman MS. Delayed protection by *ESAT-6*-specific effector CD4+ T cells after airborne *M. tuberculosis* infection. *J Exp Med*. 2008; 205(10):2359–68. Epub 2008/09/10. <https://doi.org/10.1084/jem.20080353> PMID: 18779346; PubMed Central PMCID: PMC2556792.
36. Ilghari D, Lightbody KL, Veverka V, Waters LC, Muskett FW, Renshaw PS, et al. Solution structure of the *Mycobacterium tuberculosis* EsxG.EsxH complex: functional implications and comparisons with other *M. tuberculosis* Esx family complexes. *J Biol Chem*. 2011; 286(34):29993–30002. Epub 2011/07/07. <https://doi.org/10.1074/jbc.M111.248732> PMID: 21730061; PubMed Central PMCID: PMC3191040.
37. Meng L, Tong J, Wang H, Tao C, Wang Q, Niu C, et al. PPE38 Protein of *Mycobacterium tuberculosis* Inhibits Macrophage MHC Class I Expression and Dampens CD8+ T Cell Responses. *Front Cell Infect Microbiol*. 2017; 7:68. Epub 2017/03/30. <https://doi.org/10.3389/fcimb.2017.00068> PMID: 28348981; PubMed Central PMCID: PMC5346565.
38. Noss EH, Harding CV, Boom WH. *Mycobacterium tuberculosis* inhibits MHC class II antigen processing in murine bone marrow macrophages. *Cell Immunol*. 2000; 201(1):63–74. Epub 2000/05/12. <https://doi.org/10.1006/cimm.2000.1633> PMID: 10805975

39. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. *Immunity*. 2006; 24(1):105–17. Epub 2006/01/18. <https://doi.org/10.1016/j.immuni.2005.12.001> PMID: 16413927.
40. Smith VL, Cheng Y, Bryant BR, Schorey JS. Exosomes function in antigen presentation during an in vivo *Mycobacterium tuberculosis* infection. *Sci Rep*. 2017; 7:43578. Epub 2017/03/07. <https://doi.org/10.1038/srep43578> PMID: 28262829; PubMed Central PMCID: PMC5338015.
41. Srivastava S, Ernst JD. Cell-to-cell transfer of *M. tuberculosis* antigens optimizes CD4 T cell priming. *Cell Host Microbe*. 2014; 15(6):741–52. Epub 2014/06/13. <https://doi.org/10.1016/j.chom.2014.05.007> PMID: 24922576; PubMed Central PMCID: PMC4098643.
42. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. *Nat Med*. 2003; 9(8):1039–46. <https://doi.org/10.1038/nm906> PMID: 12872166.
43. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM, et al. *Mycobacterium tuberculosis* evades macrophage defenses by inhibiting plasma membrane repair. *Nat Immunol*. 2009; 10(8):899–906. Epub 2009/06/30. <https://doi.org/10.1038/ni.1758> PMID: 19561612; PubMed Central PMCID: PMC2730354.
44. Jayaraman P, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG, et al. IL-1beta promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. *J Immunol*. 2013; 190(8):4196–204. Epub 2013/03/15. <https://doi.org/10.4049/jimmunol.1202688> PMID: 23487424; PubMed Central PMCID: PMC3622150.
45. Gonzalez-Juarrero M, Orme IM. Characterization of Murine Lung Dendritic Cells Infected with *Mycobacterium tuberculosis*. *Infection and Immunity*. 2001; 69(2):1127–33. <https://doi.org/10.1128/IAI.69.2.1127-1133.2001> PMID: 11160010
46. Bodnar KA, Serbina NV, Flynn JL. Fate of *Mycobacterium tuberculosis* within murine dendritic cells. *Infect Immun*. 2001; 69(2):800–9. Epub 2001/02/13. <https://doi.org/10.1128/IAI.69.2.800-809.2001> PMID: 11159971; PubMed Central PMCID: PMC97955.
47. Serbina NV, Flynn JL. Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of *Mycobacterium tuberculosis*-infected mice. *Infect Immun*. 1999; 67(8):3980–8. Epub 1999/07/23. PMID: 10417164; PubMed Central PMCID: PMC96683.
48. Nepal RM, Vesosky B, Turner J, Bryant P. DM, but not cathepsin L, is required to control an aerosol infection with *Mycobacterium tuberculosis*. *Journal of Leukocyte Biology*. 2008; 84(4):1011–8. <https://doi.org/10.1189/jlb.1207852> PMID: 18591414
49. Serbina NV, Liu CC, Scanga CA, Flynn JL. CD8+ CTL from lungs of *Mycobacterium tuberculosis*-infected mice express perforin in vivo and lyse infected macrophages. *J Immunol*. 2000; 165(1):353–63. Epub 2000/06/22. <https://doi.org/10.4049/jimmunol.165.1.353> PMID: 10861072.
50. Cowley SC, Elkins KL. CD4+ T cells mediate IFN-gamma-independent control of *Mycobacterium tuberculosis* infection both in vitro and in vivo. *J Immunol*. 2003. PMID: 14568944.
51. Green AM, Difazio R, Flynn JL. IFN-gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during *Mycobacterium tuberculosis* infection. *J Immunol*. 2013; 190(1):270–7. Epub 2012/12/13. <https://doi.org/10.4049/jimmunol.1200061> PMID: 23233724; PubMed Central PMCID: PMC3683563.
52. Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, et al. Human CD8 T lymphocytes recognize *Mycobacterium tuberculosis* antigens presented by HLA-E during active tuberculosis and express type 2 cytokines. *Eur J Immunol*. 2015; 45(4):1069–81. <https://doi.org/10.1002/eji.201445193> PMID: 25631937.
53. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. *Mycobacterium tuberculosis*-specific CD8+ T cells preferentially recognize heavily infected cells. *Am J Respir Crit Care Med*. 2003; 168(11):1346–52. Epub 2003/09/13. <https://doi.org/10.1164/rccm.200306-837OC> PMID: 12969871.
54. Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, et al. Classically restricted human CD8+ T lymphocytes derived from *Mycobacterium tuberculosis*-infected cells: definition of antigenic specificity. *J Immunol*. 2001; 166(1):439–46. Epub 2000/12/21. <https://doi.org/10.4049/jimmunol.166.1.439> PMID: 11123322.
55. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, et al. *M. tuberculosis* and *M. leprae* translocate from the phagolysosome to the cytosol in myeloid cells. *Cell*. 2007; 129(7):1287–98. Epub 2007/07/03. <https://doi.org/10.1016/j.cell.2007.05.059> PMID: 17604718.
56. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, et al. Phagosomal rupture by *Mycobacterium tuberculosis* results in toxicity and host cell death. *PLoS Pathog*. 2012; 8(2):e1002507. Epub 2012/02/10. <https://doi.org/10.1371/journal.ppat.1002507> PMID: 22319448; PubMed Central PMCID: PMC3271072.

57. Lindstrom T, Aagaard C, Christensen D, Agger EM, Andersen P. High-frequency vaccine-induced CD8(+) T cells specific for an epitope naturally processed during infection with *Mycobacterium tuberculosis* do not confer protection. *Eur J Immunol*. 2014. <https://doi.org/10.1002/eji.201344358> PMID: [24677089](https://pubmed.ncbi.nlm.nih.gov/24677089/); PubMed Central PMCID: PMC4112357.
58. Tinaztepe E, Wei JR, Raynowska J, Portal-Celhay C, Thompson V, Philips JA. Role of Metal-Dependent Regulation of ESX-3 Secretion in Intracellular Survival of *Mycobacterium tuberculosis*. *Infect Immun*. 2016; 84(8):2255–63. Epub 2016/06/02. <https://doi.org/10.1128/IAI.00197-16> PMID: [27245412](https://pubmed.ncbi.nlm.nih.gov/27245412/); PubMed Central PMCID: PMC4962639.
59. Grotzke JE, Siler AC, Lewinsohn DA, Lewinsohn DM. Secreted immunodominant *Mycobacterium tuberculosis* antigens are processed by the cytosolic pathway. *J Immunol*. 2010; 185(7):4336–43. Epub 2010/08/31. <https://doi.org/10.4049/jimmunol.1000801> PMID: [20802151](https://pubmed.ncbi.nlm.nih.gov/20802151/); PubMed Central PMCID: PMC2988655.
60. Woodworth JS, Fortune SM, Behar SM. Bacterial protein secretion is required for priming of CD8+ T cells specific for the *Mycobacterium tuberculosis* antigen CFP10. *Infect Immun*. 2008; 76(9):4199–205. Epub 2008/07/02. <https://doi.org/10.1128/IAI.00307-08> PMID: [18591224](https://pubmed.ncbi.nlm.nih.gov/18591224/); PubMed Central PMCID: PMC2519428.
61. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. *J Exp Med*. 2010; 207(7):1409–20. Epub 2010/06/16. <https://doi.org/10.1084/jem.20091885> PMID: [20547826](https://pubmed.ncbi.nlm.nih.gov/20547826/); PubMed Central PMCID: PMC2901066.
62. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. *Immunity*. 2008; 28(2):271–84. Epub 2008/02/12. <https://doi.org/10.1016/j.immuni.2007.12.010> PMID: [18261937](https://pubmed.ncbi.nlm.nih.gov/18261937/); PubMed Central PMCID: PMC2390753.
63. Kamath A, Woodworth JS, Behar SM. Antigen-specific CD8+ T cells and the development of central memory during *Mycobacterium tuberculosis* infection. *J Immunol*. 2006; 177(9):6361–9. Epub 2006/10/24. <https://doi.org/10.4049/jimmunol.177.9.6361> PMID: [17056567](https://pubmed.ncbi.nlm.nih.gov/17056567/); PubMed Central PMCID: PMC23133654.
64. Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang, P Holst, AR Thomsen, et al. CD4 and CD8 T cell responses to the *M. tuberculosis* Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. *PLoS One*. 2009; 4(4):e5139. Epub 2009/04/10. <https://doi.org/10.1371/journal.pone.0005139> PMID: [19357780](https://pubmed.ncbi.nlm.nih.gov/19357780/); PubMed Central PMCID: PMC2663846.
65. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J. Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. *J Immunol*. 2007; 179(6):3973–81. Epub 2007/09/06. <https://doi.org/10.4049/jimmunol.179.6.3973> PMID: [17785835](https://pubmed.ncbi.nlm.nih.gov/17785835/).
66. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. *Infect Immun*. 2001; 69(5):2773–8. Epub 2001/04/09. <https://doi.org/10.1128/IAI.69.5.2773-2778.2001> PMID: [11292688](https://pubmed.ncbi.nlm.nih.gov/11292688/); PubMed Central PMCID: PMC298224.
67. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against *Mycobacterium tuberculosis*. *Infect Immun*. 2000. PMID: [10639447](https://pubmed.ncbi.nlm.nih.gov/10639447/); PubMed Central PMCID: PMC297206.
68. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid pathways regulate adaptive immunity to *Mycobacterium tuberculosis*. *Nat Immunol*. 2010; 11(8):751–8. Epub 2010/07/14. <https://doi.org/10.1038/ni.1904> PMID: [20622882](https://pubmed.ncbi.nlm.nih.gov/20622882/); PubMed Central PMCID: PMC23150169.
69. Comas I, Chakravarti J, Small PM, Galagan J, Niemann S, Kremer K, et al. Human T cell epitopes of *Mycobacterium tuberculosis* are evolutionarily hyperconserved. *Nat Genet*. 2010; 42(6):498–503. Epub 2010/05/25. <https://doi.org/10.1038/ng.590> PMID: [20495566](https://pubmed.ncbi.nlm.nih.gov/20495566/); PubMed Central PMCID: PMC2883744.
70. Coscolla M, Copin R, Sutherland J, Gehre F, de Jong B, Owolabi O, et al. *M. tuberculosis* T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens. *Cell Host Microbe*. 2015; 18(5):538–48. Epub 2015/11/27. <https://doi.org/10.1016/j.chom.2015.10.008> PMID: [26607161](https://pubmed.ncbi.nlm.nih.gov/26607161/); PubMed Central PMCID: PMC4758912.
71. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, et al. Initiation of the adaptive immune response to *Mycobacterium tuberculosis* depends on antigen production in the local lymph node, not the lungs. *J Exp Med*. 2008; 205(1):105–15. Epub 2007/12/26. <https://doi.org/10.1084/jem.20071367> PMID: [18158321](https://pubmed.ncbi.nlm.nih.gov/18158321/); PubMed Central PMCID: PMC2234384.
72. Rock JM, Hopkins FF, Chavez A, Diallo M, Chase MR, Gerrick ER, et al. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. *Nature Microbiology*. 2017; 2:16274. <https://doi.org/10.1038/nmicrobiol.2016.274> PMID: [28165460](https://pubmed.ncbi.nlm.nih.gov/28165460/)

73. Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA. Generation of T-cell receptor retrogenic mice. *Nat Protoc.* 2006; 1(1):406–17. Epub 2007/04/05. <https://doi.org/10.1038/nprot.2006.61> PMID: [17406263](https://pubmed.ncbi.nlm.nih.gov/17406263/).
74. Bettini ML, Bettini M, Nakayama M, Guy CS, Vignali DA. Generation of T cell receptor-retrogenic mice: improved retroviral-mediated stem cell gene transfer. *Nat Protoc.* 2013; 8(10):1837–40. Epub 2013/09/07. <https://doi.org/10.1038/nprot.2013.111> PMID: [24008379](https://pubmed.ncbi.nlm.nih.gov/24008379/); PubMed Central PMCID: [PMCPMC3832243](https://pubmed.ncbi.nlm.nih.gov/PMC3832243/).